CDH22

Across TCGA pan-cancer cohorts, CDH22 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CDH22’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CDH22 RNA is repressed in tumor relative to normal tissue. In most cancer types CDH22 is over-expressed in tumor, although a few such as HNSC and UCEC show the opposite, repressed pattern.

HNSC, THCA, and UCEC are the cancer types where CDH22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDH22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−1.021	<.001	12	view →
THCA	Male	III,IV	+2.057	<.001	11	view →
UCEC	All	II,III,IV	−1.792	.001	6	view →
BRCA	All	III,IV	−0.446	<.001	6	view →
LIHC	All	All	+0.391	.014	3	view →
READ	All	All	−0.287	.003	3	view →
STAD	All	III,IV	−0.572	.003	2	view →
PRAD	All	All	−0.548	<.001	2	view →
COAD	Male	All	−0.159	.002	2	view →
ESCA	All	All	−0.902	.041	1	view →
KIRP	Male	III,IV	+0.624	.045	1	view →
LUSC	All	All	+0.445	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CDH22–HNSC

Open the HNSC breakdown →